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The Toll–Like Receptor 2/6 Agonist, 
FSL–1 Lipopeptide, Therapeutically 
Mitigates Acute Radiation 
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Joseph R. Merrill5, Gregory D. Sempowski6, W. June Brickey1 & Jenny P.-Y. Ting1,7
Risks of radiation exposure from nuclear incidents and cancer radiotherapy are undeniable realities. 
These dangers urgently compel the development of agents for ameliorating radiation–induced 
injuries. Biologic pathways mediated by myeloid differentiation primary response gene 88 (MyD88), 
the common adaptor for toll–like receptor (TLR) and Interleukin–1 receptor signaling, are critical 
for radioprotection. Treating with agonists prior to radiation enhances survival by activating TLR 
signaling, whereas radiomitigating TLR–activating therapeutics given after exposure are less defined. 
We examine the radiomitigation capability of TLR agonists and identify one that is superior for its 
efficacy and reduced toxic consequences compared to other tested agonists. We demonstrate that the 
synthetic TLR2/6 ligand Fibroblast–stimulating lipopeptide (FSL–1) substantially prolongs survival in 
both male and female mice when administered 24 hours after radiation and shows MyD88–dependent 
function. FSL–1 treatment results in accelerated hematopoiesis in bone marrow, spleen and periphery, 
and augments systemic levels of hematopoiesis–stimulating factors. The ability of FSL–1 to stimulate 
hematopoiesis is critical, as hematopoietic dysfunction results from a range of ionizing radiation doses. 
The efficacy of a single FSL–1 dose for alleviating radiation injury while protecting against adverse 
effects reveals a viable radiation countermeasures agent.
Deliberate or accidental radiation release in the cases of terrorism and nuclear warfare or energy plant and waste 
facility explosions respectively, will expose a diverse population to various degrees of penetrating ionizing radi-
ation. Therefore, medical interventions that can be administered to counteract injury associated with radiation 
are critically needed1,2. As directed by the U.S. Department of Homeland Security (https://www.dhs.gov/topic/
nuclear-security)3 and recommended by an NIH panel (https://www.niaid.nih.gov/topics/radnuc/program/
Pages/FocusedResearchDevelopment.aspx)4, immediate goals for radiation countermeasures include the devel-
opment and expansion of products that effectively prevent or treat radiation injury5. An ideal medical inter-
vention following radiation is defined by the following properties: (1) administration at 24 hours or more post 
exposure, (2) independent of sex or age, and (3) application to individuals exposed to a variety of radiation doses.
Acute radiation syndrome (ARS) is a disease state that occurs following partial or whole body exposure to 
ionizing radiation. ARS can be further characterized into hematopoietic (H–ARS), gastrointestinal (GI) and 
cerebrovascular syndromes, which develop based on the type, dose and rate of radiation received. H-ARS is 
observed at lower doses of radiation (200–600 rad), but also persists in tandem with GI and cerebrovascular 
syndromes, which occur only upon exposure to higher doses (600–1000 rad). Medical treatments, therefore, tar-
geting hematopoiesis would be vital during a mass casualty event.
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Replenishment of hematopoietic sites is critical for recovery following radiation exposure. Regeneration of 
the hematopoietic system occurs successfully through multiple mechanisms6. Hematopoiesis is driven, in part, 
by various growth factors, including granulocyte colony-stimulating factor (G-CSF), erythropoietin (EPO) and 
thrombopoietin (TPO). These factors are thought to drive proliferation of granulocytes, erythroid cells, and meg-
akaryocytes, respectively, though some degree of cross-regulation may occur between lineages. Beyond driving 
granulocyte proliferation, G-CSF can also impact the function of lymphoid lineages7. In addition to growth fac-
tors, TLR receptors found on progenitor cells utilize MyD88-dependent mechanisms to drive cellular repopula-
tion following insults to the hematopoietic system8. Furthermore, regulation of hematopoiesis can be driven by 
upregulating growth factors through TLR signaling9,10. Importantly, a correlation between G-CSF and TLR2–
dependent signaling has been demonstrated10,11.
MyD88–dependent TLR signaling is immune stimulatory and has been shown to induce protective mecha-
nisms against radiation12. Since the seminal articles reported the unexpected finding that the TLR5 agonist flagel-
lin provides radioprotection13,14, other TLR ligands have been tested as radioprotectors through administration 
prior to partial or total body irradiation. In most cases, these studies demonstrated improved survival and protec-
tion, with accelerated hematopoiesis and/or inhibition of apoptosis within the GI tract13,15–19. Such radioprotec-
tion has been observed using ligands specific to TLR2, TLR3, TLR4 and TLR51,2,13,15–25. However, the majority of 
these studies examined the use of ligands prior to radiation exposure, characterizing radioprotective mechanisms, 
whereas activity of these TLR ligands as radiomitigators given post radiation exposure is less understood.
The study of TLR2 ligands has enhanced the development of novel radiation countermeasures through 
broadening the understanding of how these immune stimulatory agonists function16,19,21,26. Indeed, the use 
of lipopeptide–based TLR2–mediated ligands is thought to be critical for driving cytokine– and chemok-
ine–based responses that target H–ARS19,21,22. The TLR2/6 ligand, Fibroblast–stimulating lipopeptide FSL–1 
(Pam2CGDPKHPKSF), contains a diacylglycerol structure similar to Pam2CSK4 and has been shown to play 
critical roles in immune cell maturation, Th2 immunity and protection from infections27–30. Whether FSL–1 
serves a role in counteracting radiation–induced injury has not been determined.
This study focuses on elucidating the radiomitigation effects of FSL–1, a different class of TLR ligand that 
activates TLR2/6, and understanding its role in improving hematopoietic responses associated with ARS, thereby 
demonstrating capacity to function as medical countermeasures against radiation. Herein, we examine the ability 
of a variety of TLR ligands to confer protection from H–ARS when administered at least 24 hours post radia-
tion exposure. We identify the TLR2/6 ligand FSL–1 as a potent radiomitigator that was superior to all others 
we tested, demonstrating exceptional efficacy and diminished adverse effects. We present data showing that the 
radiomitigation activity of FSL–1 is sex–independent and MyD88–dependent. Furthermore, we determine that a 
single administration of FSL–1 positively impacts hematopoiesis and induces G–CSF production following acute 
radiation injury. Overall, these data reveal that the immune stimulatory effects of FSL–1 mitigate radiation injury 
by accelerating hematopoietic recovery at multiple sites following radiation exposure and promoting survival. 
Lastly, this report illuminates the benefits of FSL–1 as a potential therapeutic for victims of radiation exposure by 
nuclear incidents as well as for patients receiving radiotherapy.
Results
The radiomitigation capabilities of TLR ligands are tested. To examine the role of TLR ligands as 
radiomitigators, C57BL/6 mice were exposed to ionizing gamma radiation (9.2 Gy) from a cesium source, fol-
lowed by administration of TLR ligands via intraperitoneal (i.p.) injections one day after radiation. We examined 
the impact of CpG–ODN2395 (CpG, TLR9 agonist), Flagellin FliC (Fla, TLR5 agonist), MPLA (TLR4 agonist) or 
FSL–1 (Pam2CGDPKHPKSF, TLR2/6 agonist) in comparison to physiological water (no treatment, NT). Dosing 
of each ligand was chosen based on previous work14,17,18,21,22,31 and conducting experiments with a reasonable 
number of experimental subjects.
Thirty–day survival of non–treated male C57BL/6 mice exposed to 9.2 Gy total body irradiation (TBI) varied 
between replicate experiments from 0–50% (mean 22.4%; Table 1). Control mice succumbed to the effects of 
radiation by approximately 2 weeks post TBI (Fig. 1a), as defined by weight loss greater than 25% and/or a clinical 
score greater than 15 that encompasses seven body parameters (shown in Supplementary Table S1). Only 1 of 
10 mice treated with CpG (10%) survived for 30 days post TBI compared to 0% of non–treated mice (Fig. 1a). 
Expt. n
No treatment FSL−1 (0.25 mg/kg)
No. Surviving for 30 days Survival (%) n No. Surviving for 30 days Survival (%)
1 20 6 30.0 20 19 95.0
2 4 2 50.0 6 6 100.0
3 5 0 0.0 5 5 100.0
4 10 0 0.0 10 5 50.0
5 5 0 0.0 8 5 62.5
6 7 2 28.6 5 2 40.0
7 10 4 40.0 9 8 88.9
8 6 1 16.7 3 3 100.0
Total 67 15 22.4* 66 53 80.3*
Table 1. Survival of non–treated or FSL–1–treated irradiated mice. *P < 0.0001 between No treatment and 
FSL−1 treatment for overall mean survival (%).
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The clinical score and weight change of CpG–treated mice was similar to that of control mice (Fig. 1b,c). Fla– or 
MPLA–treated mice did not survive beyond 17 days after TBI. Mortality of Fla– or MPLA–treated mice was asso-
ciated with an increased clinical score and substantial weight loss (Fig. 1b,c).
By contrast to the high mortality of mice treated with other TLR agonists, 30 day survival of FSL–1–treated 
mice ranged from 50–100% (mean 80.3%) over a course of 8 independent experiments (Table 1). In experiments 
directly comparing various TLR ligands, FSL–1–treated mice showed superior survival relative to mice treated 
with other agonists (Fig. 1a) (P = 0.0005). Increased survival was associated with notably decreased clinical score 
compared to non–treated (NT) irradiated mice (Fig. 1b), although no difference in weight loss was observed 
during the first 2 weeks after radiation (Fig. 1c).
Radiomitigation by FSL–1 results in fewer adverse effects than other TLR2 ligands. Several 
TLR2 ligands have been shown to exert protective and mitigative effects upon radiation exposure19,22. We further 
delineated radiomitigation activity of TLR2 ligands by irradiating male C57BL/6 mice and treating with either 
FSL–1 (TLR2/6 ligand), Pam2CSK4 (Pam2Cys–SKKKK, TLR2/6 ligand), or Pam3CSK4 (Pam3Cys–SKKKK, 
TLR1/2 ligand) at 24 hours post TBI. All three TLR2–activating ligands promoted survival (Fig. 2a), but showed 
differences in the well–being of treated animals. FSL–1 treatment resulted in lowered clinical scores and protec-
tion from weight loss as compared to control mice (Fig. 2b,c). Similarly, Pam2CSK4 and Pam3CSK4 treatment 
resulted in reduced clinical scores (Fig. 2b) and protected weight loss (Fig. 2c) as compared to control mice 
between 10 and 25 days after TBI. However, mice treated with Pam2CSK4, had an increased clinical score at day 
3 (Fig. 2b), associated with marked weight loss as compared to control mice (Fig. 2c). A trend toward worsened 
outcome, especially at days 2 and 18, was also observed in Pam3CSK4–treated mice (Fig. 2c).
To confirm that activity of FSL–1 is MyD88–dependent, C57BL/6 and Myd88–deficient (MyD88−/−) mice 
were exposed to 9.2 Gy TBI and 24 hours later, given FSL–1. All WT mice treated with FSL–1 survived for 30 
days after TBI compared to 25% of non–treated WT mice (Fig. 2d). Irrespective of treatment, all MyD88−/− mice 
succumbed to radiation injury by 8 days post TBI (Fig. 2d). The lethality increase was associated with elevated 
clinical score and diminished weight (Fig. 2e,f). Actually, radiation injury (and lethality) appeared to be accel-
erated in MyD88−/− mice, as an increase in clinical score and decreased weight was not observed in non–treated 
WT mice until 2 weeks post TBI (Fig. 2e,f).
FSL–1, a TLR2/6 ligand, shows beneficial radiomitigation properties. The effectiveness of FSL–1 
when given after radiation (radiomitigator) was examined by assessing consequences to drug treatment in 
absence of radiation, treatment of female mice after radiation and delayed administration post TBI. First, toxicity 
of FSL–1 was tested in the absence of TBI. FSL–1 treatment had no adverse effects on mouse survival, clinical 
score, or body weight when compared to naïve mice, suggesting minimal to no toxicity associated with FSL–1 
under conditions for these studies (Fig. 3a–c).
To determine if FSL–1 radiomitigation is sex–independent, female C57BL/6 mice were administered FSL–1 
at 24 hours post 9.2 Gy TBI. The 30 day survival of control females was 14.29% compared to 88.89% survival of 
females treated with FSL–1 (P = 0.002) (Fig. 3d). Survival of FSL–1–treated female mice was associated with dras-
tically diminished clinical score (Fig. 3e). Furthermore, FSL–1–treated female mice maintained body weight 15 to 
Figure 1. Treatment with TLR ligands impacts survival of irradiated mice. Male C57BL/6 mice were irradiated 
(9.2 Gy TBI) and 24 hours later, received a single i.p. injection of physiological water (no treatment, NT), 
2.5 mg/kg CpG–ODN2395 (CpG), 0.2 mg/kg Flagellin (Fla), 0.25 mg/kg MPLA, or 0.25 mg/kg FSL–1 (n = 10 
per group). (a) Survival over 30 days post TBI, (b) clinical score and (c) percent body weight change of each 
treatment group was compared to irradiated, non–treated mice (TBI, NT). Data are representative of 2 
independent experiments and are depicted as mean ± s.e.m. *P < 0.05, **P < 0.01 or ***P < 0.001 between 
treated and TBI, NT mice, with colors correlating to treatment group. Arrows indicate time post TBI in which 
remaining mice in group began to recover.
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30 days post TBI, resulting in much less weight change compared to irradiated, non–treated female mice (Fig. 3f). 
This is the first comparison of male and female mice for TLR2–targeted radiomitigation studies.
To determine if FSL–1 treatment is effective when given later than 24 hours post TBI, C57BL/6 mice were 
administered FSL–1 at 48 hours after TBI. Although the 30 day survival of mice treated with FSL–1 at 48 hours 
post TBI was diminished compared to mice treated at 24 hours post TBI (Fig. 3g) (25% versus 50%, P = 0.0352), 
survival was still enhanced when comparing to mice receiving no treatment (Fig. 3g) (25% versus 0%, P = 0.1247). 
The capacity to evoke 25% survival rate is notable for targeting H–ARS, since most radiomitigators have not been 
examined at this delayed time or have failed when administered 48 hours after radiation22. Consistent with previ-
ous observations, no weight differences were observed between control and treated mice (Fig. 3h), with the caveat 
that all of the control mice succumbed to radiation by 2 weeks.
As ionizing radiation causes severe damage in both skin and gastrointestinal tract, the susceptibility of patients 
to systemic infection from endogenous and exogenous organisms prominently increases following radiation 
exposure32. Antibiotics treatment has been considered as an important component of any radiation mitigation 
strategy33. To examine whether FSL–1 synergizes with antibiotics to augment radioprotection, ciprofloxacin, a 
broad–spectrum fluoroquinolone previously tested in an acute radiation murine model34, was administrated 
to C57BL/6 mice or combined with FSL–1 treatment after animals were subjected to 8.8 Gy TBI. To avoid the 
added stress of daily injections and handling of irradiated mice, ciprofloxacin was provided ad libitum in the 
drinking water and as wetted feed, starting at day 4 and maintained throughout the 30 day monitoring period. 
Ciprofloxacin alone had a slight beneficial effect that was not statistically different from the profiles of survival, 
clinical score or weight change of animals receiving TBI with no treatment (Fig. 3i–k). The lack of a distinct effect 
of antibiotics may be partially due to the fact that these mice were housed in a specific pathogen–free environ-
ment. The 30 day survival of mice treated with FSL–1 combined with ciprofloxacin was similar to the survival 
profile of mice treated with FSL–1 only (Fig. 3i). Furthermore, there were no substantial differences in clinical 
Figure 2. Radiomitigation is TLR2 and MyD88 specific. Male C57BL/6 mice were administered physiological 
water (NT), 0.25 mg/kg FSL–1, 0.25 mg/kg Pam2CSK4 or 0.25 mg/kg Pam3CSK4 at 24 hours after 9.2 Gy TBI 
exposure. (a) Survival was recorded through 30 days post TBI. Data is cumulative of 2 independent experiments 
with n = 4–6 mice per group per experiment. (b) Clinical score and (c) percent body weight change were 
assessed in comparison to irradiated, non–treated controls (TBI, NT). C57BL/6 or MyD88−/− male and female 
mice were administered physiological water (NT) or 0.25 mg/kg FSL–1 at 24 hours post 9.2 Gy TBI. (d) Survival, 
(e) clinical score, and (f) percent body weight change were assessed for 30 days post TBI. Data is representative 
of 2 experiments with n = 6 to 10 as indicated in legend. Data are shown as mean ± s.e.m. *P < 0.05, **P < 0.01, 
***P < 0.001 or ****P < 0.0001 between treated and TBI, NT mice, with colors correlating to treatment group.
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Figure 3. FSL–1, a TLR2/6 ligand, demonstrates radiomitigation properties. Toxicity was tested in male C57BL/6 
mice, comparing physiologic water (NT) to 0.25 mg/kg FSL–1 treatment. (a) Survival, (b) clinical score, and (c) 
percent body weight change of mice were monitored over 30 days. Sex independency was tested by treating female 
C57BL/6 mice exposed to 9.2 Gy TBI with physiological water (NT) or 0.25 mg/kg FSL–1 given 24 hours post TBI. 
(d) Survival, (e) clinical score and (f) percent body weight change of female mice were assessed for 30 days. The 
effectiveness of FSL–1 treatment was compared by delivering physiological water (NT) or 0.25 mg/kg FSL–1 at 24 or 
48 hours after 8.8 or 9.2 Gy TBI. (g) Survival and (h) percent body weight change were assessed for 30 days. Efficacy 
of FSL–1 combined with antibiotics treatment was evaluated by delivering physiological water (NT) or 0.25 mg/
kg FSL–1 at 24 hours after 8.8 Gy TBI. On days 4 to 30 post TBI, ciprofloxacin was provided in autoclaved acidified 
water ad libitum from sipper tubes and also in wetted feed. Controls received no ciprofloxacin support, but did 
receive acidified water and moistened regular feed. (i) Survival, (j) clinical score and (k) percent body weight change 
were assessed for 30 days. Data (mean ± s.e.m.) are representative of 2 independent experiments with n = 5 to 15 as 
indicated in panel legends. *P < 0.05, **P < 0.01 or ****P < 0.0001 between treated and TBI, NT mice, with color 
representing treatment group. Arrows indicate time post TBI in which remaining mice in group began to recover.
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score or body weight change between these two groups, which showed reduced clinical scores and rebounded 
weight maintenance (Fig. 3j,k). This suggests that FSL–1 administered in a single dose functions as an effective 
radiation countermeasures in the absence of antibiotics support.
FSL–1 stimulates extramedullary hematopoiesis. In mice, hematopoiesis is common in extramed-
ullary sites (termed EMH), thereby allowing examination of H–ARS and recovery in bone marrow, peripheral 
blood, as well as in splenic parenchyma. First, we noted that spleens were distinctively smaller (indicative of H–
ARS) in irradiated mice compared to non–irradiated mice at days 3 and 9 post TBI, regardless if also treated with 
FSL–1 (Fig. 4a; see Supplementary Fig. S1). At 17 days post TBI, spleens of FSL–1–treated irradiated mice showed 
recovery, as indicated by similar spleen sizes to spleens of non–irradiated mice (Fig. 4a; see Supplementary 
Fig. S1). Furthermore, spleens of FSL–1–treated, irradiated mice were appreciably heavier than non–treated, irra-
diated (TBI, NT) mice at 17 days (Fig. 4a). The size and appearance of spleens from FSL–1–treated mice remained 
similar to that of non–irradiated mice through 31 days following TBI, whereas the spleens of TBI, NT mice were 
radically enlarged at this later time point (Fig. 4a).
To examine how FSL–1 treatment contributes to EMH, hematologic features of spleens were examined. In 
non–irradiated mice, irrespective of FSL–1 treatment, splenic architecture was normal, with white pulp con-
taining well–developed lymphocyte–rich follicles and red pulp containing venous sinusoids and scattered 
hematopoietic elements (Fig. 4b,c; see Supplementary Fig. S1). At 3 and 9 days post TBI, appreciable atrophy and 
lymphocyte depletion were observed in spleens of both non–treated and FSL–1–treated irradiated mice (Fig. 4b,c; 
see Supplementary Fig. S1). By 17 days post TBI, spleens of FSL–1–treated, irradiated mice had considerably 
more EMH than non–treated, irradiated mice, with splenic architecture approaching normal by day 31 in the 
FSL–1–treated mice (Fig. 4b,c; see Supplementary Fig. S1).
FSL–1 enhances bone marrow hematopoiesis. Given increased EMH evident in spleens, we then 
explored the effect of FSL–1 on bone marrow (BM). Regardless of drug treatment, femurs of non–irradiated mice 
were normal in appearance (95–100% cellularity; Fig. 5a,b; see Supplementary Fig. S2). Consistent with radiation 
injury resulting in massively reduced cellularity, extensive stromal injury and cell death were observed in BM 
from non–treated and FSL–1–treated mice 3 days post TBI (Fig. 5a,b; see Supplementary Fig. S2). By day 9 post 
TBI, repopulation of viable adipocytes, indicative of repair processes, was observed in the BM of non–treated 
and FSL–1–treated mice, along with repopulation of hematopoietic cells in FSL–1–treated mice only (Fig. 5a; 
see Supplementary Fig. S2). By 17 days post TBI, mean BM cellularity in FSL–1–treated irradiated mice was 
Figure 4. FSL–1 drives splenic EMH. Male C57BL/6 mice were administered physiological water (NT) or 
0.25 mg/kg FSL–1 at 24 hours post 9.2 Gy TBI (n = 6–15 mice per group). (a) Spleens were harvested at 3, 9, 17 
and 31 days after TBI, with weights shown. Each symbol represents one mouse. (b) Representative images of 
H&E stained spleen sections are shown. (c) Spleen EMH is quantified based on a scale described in Methods 
and represented as mean ± s.e.m. All data are representative of 3 independent experiments. ****P < 0.0001 
between TBI, NT and TBI, FSL–1–treated mice. ++P < 0.01 or +++P < 0.001 between TBI, FSL–1 and FSL–1–
treated mice. δP < 0.05, δδδP < 0.001 or δδδδP < 0.0001 between TBI, NT and NT control mice.
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Figure 5. FSL–1 drives medullary hematopoiesis. Male C57BL/6 mice were given physiological water (NT) or 
FSL–1 at 24 hours post TBI. Femurs were collected at days 3, 9, 17 and 31 post TBI (n = 6–15 per group). (a) 
Representative images of H&E stained femur sections are shown. (b) Quantitative analysis of bone marrow 
(BM) percent cellularity and (c) BM cell counts per femur are presented. NT, non–radiated and not treated 
with FSL–1; FSL–1, non–radiated, but treated with FSL–1; TBI, NT, radiated and not treated with FSL–1; TBI, 
FSL–1, radiated and treated with FSL–1. (d) Representative modified Wright stained cytology images are 
shown. (e) BM cellular differentiation is represented as ratio of Granulocytic to Erythroid cells (G:E ratio). 
(f) Representative images of Ki67 stained femur sections are shown. (g) Quantitative analysis of Ki67 positive 
cells (% of total cells) is summarized from 3 random fields of view. The data includes 713 cells counted for 
NT samples, 1370 cells counted for FSL–1–treated samples, 858 cells counted for TBI, NT samples and 1979 
cells counted for TBI, FSL–1 samples. Data are representative of 3 independent experiments. Graphed data 
are mean ± s.e.m. **P < 0.01 or ***P < 0.001 between TBI, NT and TBI, FSL–1–treated mice. +P < 0.05, 
++P < 0.01 or ++++P < 0.0001 between TBI, FSL–1–treated and FSL–1 only treated mice. δP < 0.05, δδδP < 0.001 
or δδδδP < 0.0001 between TBI, NT and NT control mice. In c, e and g, each symbol represents one mouse.
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notably increased compared to non–treated, irradiated mice (Fig. 5a,b). By 31 days post TBI, BM cellularity of 
FSL–1–treated mice ranged from 50–90%, which was considerably elevated compared to non–treated, irradiated 
mice (Fig. 5a,b). Femur cell counts mirrored the phenotype observed in the histologic samples, with femoral cell 
numbers of FSL–1–treated irradiated mice rebounding to numbers found in non–irradiated mice (Fig. 5c) with 
a similar kinetic profile.
To further characterize hematopoiesis in the femurs of irradiated mice, cytologic preparations were evaluated 
for the relative proportion of granulocytic and erythroid lineages (G:E ratio) (Fig. 5d,e). A normal G:E ratio is 
approximately 2, as observed in non–irradiated mice independent of FSL–1 treatment (Fig. 5d,e). The G:E ratio 
was appreciably diminished by 9 and 17 days following TBI in non–treated and FSL–1–treated mice, consistent 
with the earlier recovery of the erythroid lineage (Fig. 5e). As depicted in the representative cytology image, an 
increased G:E ratio in the femurs of FSL–1–treated, irradiated mice was observed by day 31 post TBI, whereas a 
diminished G:E ratio persisted in irradiated, but non–treated mice (Fig. 5d,e).
To further investigate BM cell regeneration, Ki67 staining was conducted on femur samples and proliferating 
Ki67+ cells were tabulated. In the absence of radiation, FSL–1 treatment showed no influence on BM cell pro-
liferation as compared with the non–treated group (Fig. 5f,g). By 8 days post TBI, in the absence of FSL–1 radi-
omitigation, massive cell death and scarce cell proliferation were found in BM samples. On the other hand, FSL–1 
treatment effectively supported the recovery of Ki67+ cells to a level that was not statistically different from what 
was found in the non–irradiation groups (Fig. 5f,g). Taken together, these results suggest that FSL–1 dramatically 
enhances cellular proliferation that contributes to the accelerated regeneration of bone marrow cells.
FSL–1 promotes peripheral blood recovery. In addition to BM depletion, consequences of radiation 
can manifest as cytopenia in peripheral blood. Previously, administration of the TLR2 ligand CBLB613, a day 
prior to radiation, resulted in the enhancement of peripheral blood cellularity within the first 48 hours following 
TBI19; however, no other time points were examined to determine if this increase was achievable with post–
radiation dosing. Here, FSL–1 treatment alone did not alter white blood cell (WBC) or red blood cell (RBC) 
populations in the periphery of non–irradiated C57BL/6 mice (Fig. 6). To assess the effects of post–radiation 
FSL–1 treatment on cytopenia, peripheral blood samples were analyzed at days 3, 9, 17 and 31 after 9.2 Gy TBI. 
We found that radiation caused partial to complete depletion of all blood cell populations through 17 days after 
TBI, without any protection by FSL–1 treatment (Fig. 6). By 31 days post TBI, WBC (granulocyte, monocyte) 
and platelet populations were nearly fully or partially restored to baseline levels in FSL–1–treated, irradiated mice 
as compared to non–treated mice (Fig. 6a,c,d,f). Furthermore, RBCs were elevated in FSL–1–treated, irradiated 
mice at this later time as compared to non–treated, irradiated mice (Fig. 6e). These data point to the promotion of 
peripheral blood cell recovery with FSL–1 treatment after radiation.
FSL–1–induced G–CSF correlates with enhanced hematopoiesis. Early response biomarkers such 
as hematopoietic proteins and blood cell counts have been used as indicators of radiation exposure in order to 
assess severity of dose and efficacy of treatments35,36. To determine if enhanced H–ARS recovery in FSL–1–treated 
mice is due to cooperation between TLR2/6 stimulation and growth factors, serum factors were measured at 3, 9, 
17 and 31 days post TBI plus or minus FSL–1 treatment. Using two methods of detection, we found that FSL–1 
caused a shift in the kinetics of serum G–CSF. Specifically, G–CSF was dramatically elevated in FSL–1–treated, 
irradiated mice at day 3 post TBI, followed by a steady decline observed through day 31 after TBI, when levels 
were similar to that of non–irradiated mice (Fig. 7a,b). Conversely, G–CSF was low at day 3, detectable at day 9 
and peaked later by day 17 in irradiated mice that were not treated with FSL–1 (Fig. 7a,b). Thus, FSL–1 induced a 
drastically elevated level of G–CSF soon after TBI (day 3 post exposure) when compared to non–treated, irradi-
ated controls. This is consistent with higher levels of hematopoiesis observed with FSL–1 treatment (as shown in 
Figs 4–5). We examined other serum biomarkers by luminex analysis, but did not find any notable correlations 
with FSL–1 treatment and/or radiation (see Supplementary Table S2), except for FSL–1–induced serum LIX/
Cxcl5 or granulocyte chemotactic protein 2, which is involved in the mobilization of hematopoietic stem cells to 
the periphery37. Also, delayed elevation in EPO and TPO was evident by 9 and 17 days after irradiation in both 
non–treated and FSL–1–treated samples. FSL–1 treatment did not alter EPO or TPO levels, except for slight 
reductions in TPO at days 17 and 31 after TBI (Fig. 7c,d). In summary, these data indicate that FSL–1 supports 
hematopoietic recovery through the induction of stimulating factors, such as G–CSF.
Discussion
The results in this report show that ligands for TLR2/6, but not for TLR4, 5 nor 9, promoted survival when 
administered at 24 hours following TBI. Variability in protection with other TLR ligands compared to previously 
published work is likely due to ligand specificity (i.e. Flagellin FliC used here versus CBLB502), time of admin-
istration, mouse strain and/or radiation source13,17,18 as well as tissue expression patterns of effector receptors. 
However, head–to–head comparison indicates that FSL–1 confers considerably greater protection with a dearth 
of associated adverse effects. FSL–1 provides substantial protection from radiation injury when administered 
24 hours post TBI. Although only modest radiomitigation remains when FSL–1 was administered at 48 hours 
(25% survival), this level of protection is still notably greater than other published countermeasures when 
administered at this delayed time after irradiation22. Importantly, effectiveness of FSL–1 as a radiomitigator is 
sex–independent.
It is well understood that MyD88–dependent signaling is crucial for recovery following radiation21,22,31,38. 
Furthermore, it has been shown that TLR ligands administered prior to radiation mediate effects through 
MyD88–dependent mechanisms. Similarly, data herein show that the effects of FSL–1 are MyD88–dependent. 
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Independent of treatment with FSL–1, MyD88−/− mice succumb to radiation injury by 10 days post exposure. 
Moreover, death in MyD88−/− mice is substantially accelerated as compared to WT controls treated with FSL–1.
Data herein demonstrate that FSL–1 treatment drives hematopoiesis in medullary and extramedullary sites, 
thereby enhancing recovery following sub–lethal radiation. Given that circulating G–CSF levels are elevated in 
the periphery of FSL–1–treated mice as early as 3 days post TBI, TLR2 stimulation may accelerate hematopoiesis 
in a G–CSF–dependent manner. This model is consistent with previous work noting G–CSF as a biomarker for 
radioprotection with the TLR5 agonist, CBLB50225. G–CSF is a growth factor that drives granulocyte and stem 
cell production within the BM, as well as the recruitment of cells into the periphery. Collaboration can also occur 
between G–CSF and other hematopoietic growth factors to impact lymphoid and erythroid cell development 
and functions. Recent studies suggest both a synergistic and antagonistic relationship between TLR2 ligands and 
G–CSF in the regulation of hematopoiesis10,39,40. While FSL–1 administered post TBI is associated with increased 
G–CSF secretion and accelerated hematopoiesis, delayed enhancement of G–CSF found within serum of non–
treated, irradiated mice is likely a compensatory mechanism to restore severe lymphatic tissue damage.
Beyond the use for accidental nuclear radiation exposure, FSL–1 treatment should be considered for appli-
cation alone or in combination with cancer–related radio– or chemotherapies. G–CSF has been approved by the 
U.S. FDA for the prevention of febrile neutropenia in cancer patients who receive myelosuppressive chemother-
apy. It will be of interest to test FSL–1 in cancer models for determining its potential application in cancer therapy. 
There is substantial research demonstrating the benefits of G–CSF in protecting individuals from adverse effects, 
including insults to the hematopoietic system associated with radio– or chemotherapies41,42. Specifically, G–CSF 
contributes to the mobilization of hematopoietic cells in cancer patients undergoing various treatments43. We 
Figure 6. FSL–1 enhances peripheral blood repopulation. Male C57BL/6 mice were administered physiological 
water (NT) or FSL–1 at 24 hours post 9.2 Gy TBI. Peripheral blood was collected with (a) white blood cell, (b) 
lymphocyte, (c) granulocyte, (d) monocyte, (e) red blood cell and (f) platelet populations counted. The number 
of mice examined are: n = 3 for NT and FSL–1 only groups; n = 6 for TBI, NT mice; n = 6–9 (days 3 and 9); 
n = 7 (day 17) and n = 10 (day 31) for TBI, FSL–1–treated mice. Data are represented by mean ± s.e.m., and are 
tallied from 2–3 independent experiments. Each symbol represents one mouse. *P < 0.05 or **P < 0.01 between 
TBI, NT and TBI, FSL–1–treated mice. +P < 0.05, ++P < 0.01, +++P < 0.001 or ++++P < 0.0001 between TBI, 
FSL–1 and FSL–1 only treated mice. δP < 0.05, δδP < 0.01, δδδP < 0.001 or δδδδP < 0.0001 between TBI, NT and NT 
control mice.
www.nature.com/scientificreports/
1 0SCIeNTIfIC RepoRtS | 7: 17355  | DOI:10.1038/s41598-017-17729-9
suggest that FSL–1–driven TLR2/6 stimulation can promote increased G–CSF, therefore resulting in enhanced 
hematopoietic cell mobilization and regeneration. This mechanism has been observed in the intestine where 
TLR2 stimulation drives monocyte differentiation in a G–CSF–dependent manner39. In a model of graft versus 
host disease, it was demonstrated that G–CSF mobilization of myeloid cells is diminished in Tlr2−/− mice and 
in mice treated with TLR2 inhibitors40. Our radiation exposure data suggest that TLR2/6 stimulation by FSL–1 
drives G–CSF, which then mediates hematopoietic cell mobilization.
Although G–CSF treatments provide substantial therapeutic benefits, several studies have raised concerns 
about the safety of this growth factor33,44–46. One study raised the concern of increased long term risks for devel-
oping myelodysplasia (MDS) and acute myeloid leukemia (AML) in stem cell donors who receive repeated G–
CSF dosing for cell mobilization47. Another study reported a trend toward increased incidence of MDS/AML in 
breast cancer patients receiving G–CSF support with chemotherapy treatment48. Lastly, severe congenital neu-
tropenia patients who were treated with higher doses of G–CSF showed a more than 3–fold increased risk of 
transformation to MDS/AML compared with those who received lower doses49,50. In contrast in our experiments, 
a subset of mice that received FSL–1 treatment after total body radiation have remained alive for more than 600 
days, without the presentation of diseases or cancers. Furthermore, we performed Magnetic Resonance Imaging 
(MRI) to analyze these long term survivors and found no physiologic changes in the brain, gut, kidney or spleen 
(see Supplementary Fig. S3). These observations provide impetus to suggest that FSL–1 may be a safer treatment 
compared to G–CSF.
In 2015, G–CSF was approved as a drug by the U.S. FDA for treating radiation–induced hematopoietic dam-
age. It has also been approved by the Centers for Disease Control and Prevention for administration to victims 
exposed to a radiological nuclear incident. The radio–protective efficacy of G–CSF is dependent on drug dose 
as well as drug treatment schedule. Shakhov et al. showed G–CSF or Neupogen® (Amgen, Inc.) increased the 
survival of irradiated mice only when injected subcutaneously daily from days 1 to 16 after 7.96 Gy irradiation22. 
In our study, a single dose of FSL–1 given 24 hours post–radiation provided as high as 80% protection, which 
suggests FSL–1 may be superior in convenience and effectiveness as a radiation mitigator. Therefore, by extension, 
it is possible that FSL–1 may provide greater potential in comparison to the commonly used G–CSF treatment in 
cancer patients undergoing radio– and/or chemotherapy treatment.
Methods
Animals. Eight to twelve week old mice were used for all studies. C57BL/6 mice (WT, Jackson Laboratories, 
Bar Harbor, ME) and MyD88−/− mice (originally from Dr. Shizou Akira, Osaka University, Osaka, Japan) were 
bred under pathogen–free conditions at the University of North Carolina Chapel Hill (UNC–CH) facilities 
accredited by the Association for the Assessment and Accreditation of Laboratory of Animal Care. For some stud-
ies, 6 week old male C57BL/6 mice were ordered from Jackson Laboratories and allowed 2–4 weeks of acclimation 
prior to experimentation. All protocols were established based on the Guide for the Care and Use of Laboratory 
Animals (2011) and approved by the UNC–CH Institutional Animal Care and Use Committee.
Figure 7. G–CSF biomarker is elevated early in FSL–1–treated mice. Male C57BL/6 mice were administered 
physiological water (NT) or FSL–1 at 24 hours post 9.2 Gy TBI. Peripheral blood was collected on days 3, 9, 17 
and 31 post TBI. G–CSF levels were assessed by (a) luminex or (b) ELISA. (c) EPO and (d) TPO levels were 
assessed by ELISA. Luminex data represents one experiment, while ELISA data are cumulative of 2 independent 
experiments. Each symbol represents one mouse. *P < 0.05 or **P < 0.01 between TBI, NT and TBI, FSL–1–
treated mice. +P < 0.05, ++P < 0.01 or ++++P < 0.0001 between FSL–1 and TBI, FSL–1–treated mice.
www.nature.com/scientificreports/
1 1SCIeNTIfIC RepoRtS | 7: 17355  | DOI:10.1038/s41598-017-17729-9
Total body irradiation. Total body irradiation (TBI) of mice was performed using an attenuator (X–302) 
with a 137Cesium gamma–ray irradiating source (Mark I, Model 68–1, J.L. Shepard & Associates, San Fernando, 
CA). Alternatively, a Gammacell® 40 Exactor 137Cesium source (Serial no. 265, Best Theratronics, Ottawa, 
Ontario) was used for γ–irradiation, with dosimetry variation of +/− 0.07 Gy as determined with phantoms by 
Dr. Ke Sheng, UCLA, Los Angeles, CA. For TBI, non–anesthetized mice were placed in ventilated plastic pie cages 
and exposed to 8.8 Gy or 9.2 Gy TBI. Following TBI, mice were housed in sterile autoclaved cages and provided 
standard chow and water ad libitum unless otherwise noted.
Mice were monitored for changes in body weight, surface body temperature and body parameters through 
30 days post TBI unless otherwise noted. A clinical score was determined using a cumulative scoring system 
(see Supplementary Table S1) based on weight loss, temperature change, physical appearance, posture, mobil-
ity, food consumption and hydration51. Immediate indications for euthanasia included: weight loss greater than 
25% of starting body weight, unconsciousness, an inability to remain upright, agonal respiration (gasping) or 
convulsions.
TLR ligand administration. All TLR ligands (InvivoGen, San Diego, CA) were resuspended in sterile, vac-
cination–grade physiological water. Twenty–four hours following TBI, mice were given an i.p. injection of phys-
iological water (no treatment, NT), 2.5 mg/kg CpG–ODN 2395 (tlrl–2395), 2.0 mg/kg Flagellin FliC (vac–fla), 
0.25 mg/kg MPLA (tlrl–mpla), 0.25 mg/kg FSL–1 (tlrl–fsl), 0.25 mg/kg Pam2CSK4 (tlrl–pm2s–1) or 0.25 mg/kg 
Pam3CSK4 (tlrl–pms). The total volume administered per mouse ranged from 50–70 μl based on the weight of 
the mouse and ligand concentration.
Antibiotics Treatment. Male C57BL/6 mice received 8.8 Gy TBI and 24 hours later the mice were given an 
i.p. injection of physiological water (NT) or 0.25 mg/kg FSL–1. On days 4 to 30 post TBI, 0.67 mg/ml ciproflox-
acin (Sigma, catalog 17850) was provided in autoclaved acidified water ad libitum from sipper tubes and also as 
wetted feed in Petri dishes set on the cage bottom. Controls received no ciprofloxacin, but did receive autoclaved 
acidified water plus wetted feed on days 4 to 30 after radiation exposure. Mice were monitored for changes in 
body weight, surface body temperature and other body parameters through 30 days post TBI as described above.
Histopathology and cytology. To assess tissue pathology, isolated spleens and femurs were fixed in 10% 
neutral–buffered formalin, paraffin–embedded, and sectioned (4 micron thickness) at the UNC Lineberger 
Animal Histopathology Core Facility. Prior to paraffin–embedding, femurs underwent an additional decalcifica-
tion step in ImmunocalTM (StatLab, McKinney, TX). Slides were then stained with hematoxylin and eosin (H&E).
Slides of femur sections were also stained with Ki67 antibody (D3B5, Cell Signaling, 12202) to examine pro-
liferative capacity. Ki67 positive cells were quantified using ImageJ (Version 2.0.0–rc–46/1.50 g). Three random 
fields of view were examined. Percent of Ki67+ cells was tabulated as follows: Ki67+ DAPI+ cells/total cells per 
view of femur section, with more than 700 cells counted for each cohort.
Histologic and cytologic samples were scored by a Board Certified Pathologist (NDM) who was blinded to 
experimental conditions. Scoring of spleen histology and BM cytology were performed using an Olympus BX51 
microscope with Olympus objective lenses: PLAPON 2× (numerical aperture, na = 0.08, overall original magni-
fication 20×), UPlanFL N 4× (na = 0.13, magnification 40×), and UPlanFL N 60× (na = 1.25 Oil, magnification 
600×). Images were taken with a DP71 camera and DPController v3.3.1.292 software (Olympus, Center Valley, 
PA). Scoring of BM histology was performed using an Olympus BX43 microscope with Olympus objective lenses 
PLAPON 2× (na = 0.08, magnification 20×) and UPlanFL N 4× (na = 0.13, magnification 40×). Images were 
taken with a DP27 camera and CellSens Dimension 1.13 software (Olympus). For all microscopic studies, evalu-
ation was performed at ambient temperature. Image processing was limited to contrast adjustment and sharpen-
ing, and was performed using Adobe Photoshop CS4 v11.0.2 (Adobe, San Jose, CA).
To detail changes in spleen histology, a semi–quantitative scoring system was developed, reflecting sequential 
histologic features observed in recovering spleens from irradiated animals. In general, this scoring system was 
based on the amount and patterns of extramedullary hematopoiesis (EMH) as described here: 1, atrophy; 2, 
atrophic white pulp with less than 20% EMH; 3, atrophic white pulp with 20–60% EMH; 4, atrophic white pulp 
with 60–100% EMH; 5, early white pulp recovery with extensive EMH in red pulp; 6, well–developed white pulp 
with extensive EMH in red pulp; 7, normal spleen.
H&E stained femur sections were scored based on the overall percentage of marrow space occupied by 
hematopoietic cells as compared to adipocytes and expressed as percent bone marrow (BM) cellularity [(mar-
row space occupied by hematopoietic cells/total marrow space) ×100%]. For cytologic analysis of BM, femurs 
were flushed with Alpha–MEM media containing 10% FBS and 100 × Pen/Strept. BM cells were homogenized to 
obtain a single cell suspension, and then serially diluted to 1:1, 1:2 and 1:4 ratios. Cytospin slides were prepared 
by centrifugation for 5 minutes at 1,000 × g, fixed in methanol and stained using a modified Wright staining 
protocol. A manual differential count of 100 cells on each slide was performed, and the ratio of granulocytic to 
erythroid lineage cells was calculated.
Peripheral blood assessment. Whole blood was collected by cardiac puncture and placed in EDTA–
coated tubes. Standard hematological tests to examine WBC and RBC populations were performed by the UNC–
CH Animal Clinical Chemistry Facility using an Animal Blood Counter (Heska, Loveland, CO).
Cytokine analysis. Whole blood was collected by cardiac puncture and centrifuged to isolate serum. Serum 
samples were analyzed by Enzyme–Linked Immunosorbent Assay (ELISA) (G–CSF; MCS00, R&D Systems, 
Minneapolis, MN) or by multiplex analyte assay using Luminex technology (EMD Millipore, Darmstadt, 
Germany) according to manufacturers’ protocols.
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Statistics. All data are represented as mean ± s.e.m. Significance between multiple groups was determined 
using one–way analysis of variance (ANOVA) with the Tukey–Kramer post hoc test for multiple comparisons. 
Statistical significance of survival curves was determined using Kaplan and Meier analysis. A P–value < 0.05 was 
considered statistically significant. All statistical analyses were performed using Prism (GraphPad Software Inc, 
La Jolla, CA).
Data availability. All data generated or analyzed during this study are included in this article (and its 
Supplementary Information file).
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